Metabolic Status and Resistin in Chronic Schizophrenia Over a 2-Year Period With Continuous Atypical Antipsychotics

Therapeutic Advances in Psychopharmacology

doi 10.1177/2045125315596697

Full Text

Abstract

Available in

Date

August 5, 2015

Authors

Shinichiro Ochi

Publisher

SAGE Publications

Related search

Lipidomics Reveals Early Metabolic Changes in Subjects With Schizophrenia: Effects of Atypical Antipsychotics

Multidisciplinary

English

Metabolic Effects of Treatment With Atypical Antipsychotics

Journal of Clinical Psychiatry

English

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

International Journal of Molecular Sciences

Organic Chemistry

Molecular Biology

Theoretical Chemistry

Inorganic Chemistry

Computer Science Applications

English

Metabolic Effect of Atypical Antipsychotics

Kansas Journal of Medicine

English

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

English

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil

Applied Health Economics and Health Policy

English

Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics

American Journal of Psychiatry

English

Erratum To: Suicidality and Second Generation Antipsychotics in Schizophrenia Patients: A Case-Controlled Retrospective Study During a 5-Year Period

Psychopharmacology

English

Atypical Antipsychotics

PharmacoEconomics & Outcomes News

English